2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

• Sponsor: Virginia Commonwealth University (Other)
• Overall Status: Terminated
• CT.gov ID: NCT02624700
• Collaborator: Eli Lilly and Company (Industry), Bayer (Industry)
• Enrollment: 13
• Location: 1
• Arms: 2
• Actual Duration (Months): 41.4
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

This phase 2 clinical trial will evaluate the efficacy of the combination of pemetrexed and sorafenib in patients with recurrent or metastatic Triple Negative Breast Cancer (TNBC). Candidate pharmacodynamic and predictive biomarkers will also be evaluated.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer	Drug: Experimental Arm A: Pemetrexed; Drug: Experimental Arm A: Sorafenib; Drug: Experimental Arm B: Pemetrexed; Drug: Experimental Arm B: Sorafenib	Phase 2

Detailed Description

This study is a single-arm, open-label, phase 2 study of a regimen of dose-dense pemetrexed and sorafenib to determine the objective response rate in patients with recurrent or metastatic TNBC. Eligible patients will be those who have had disease progression during or after treatment for recurrent or metastatic disease with one previous cytotoxic chemotherapy regimen. Additionally, patients with disease progression or recurrence during or within 6 months of completion of adjuvant or neoadjuvant therapy are also eligible. Correlative studies will be conducted using blood samples and archived tumor samples.

Simon's two-stage design will be utilized in this study. In the first stage, if there are ≤ 3 patients of the first 18 efficacy-evaluable patients who have a partial or complete response, then the trial will end for futility. If ≥ 4 patients have a partial or complete response, patient accrual will continue in the second stage to add 10 more efficacy-evaluable patients.

The total sample size for the Simon's two-stage design is 35 patients. Based on enrollment of 2-3 patients per month, the expected enrollment period will be about 12-18 months.

Patients were enrolled in 2 sequential groups, referred to as "arms" for the purposes of reporting results by group. The initial group of patients were enrolled in what is referred to here as Arm A. After a study amendment patients were enrolled in what is referred to here as Arm B.

Study Design

• Study Type: Interventional
• Actual Enrollment: 13 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase 2 Study of Pemetrexed and Sorafenib for Treatment of Recurrent or Metastatic Triple Negative Breast Cancer
• Actual Study Start Date: Jan 28, 2016
• Actual Primary Completion Date: Jul 10, 2019
• Actual Study Completion Date: Jul 10, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: A: Pemetrexed + Sorafenib Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle	Drug: Experimental Arm A: Pemetrexed; Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.; Other Names: Alimta ; Drug: Experimental Arm A: Sorafenib; Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.; Other Names: Nexavar
Experimental: B: Pemetrexed + Sorafenib Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21 days of each cycle.	Drug: Experimental Arm B: Pemetrexed; Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.; Other Names: Alimta ; Drug: Experimental Arm B: Sorafenib; Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.; Other Names: Nexavar

Outcome Measures

Primary Outcome Measures

1. The Percentage of Patients With Objective Response Either Partial Response (PR) or Complete Response(CR). [2 years 3 months]

   The primary endpoint is the percentage of patients with HER2-negative metastatic breast cancer achieving an objective response (either PR or CR). Overall Response = CR+PR, based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).

Secondary Outcome Measures

1. The Duration of Progression-free Survival (PFS). [2 years 3 months]

   Progression-free survival (PFS) defined as the time (in days) from initiation of study treatment until documented disease progression or death, whichever occurs first.

2. The 2-year Survival Rate After Initial Study Treatment. [2 years 3 months]

   The proportion of patients who are alive at 2 years following initiation of study treatment.

3. Number of Participants at Risk and Affected by Adverse Events (AEs) [2 years 3 months]

   To further characterize the safety and side effect profile of the combination. All participants' AEs will be listed and summary descriptive statistics will be calculated.The Adverse events (AEs) are reported using criteria in the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria

• Unresectable adenocarcinoma of the breast involving chest wall, regional nodes, or distant site

• Breast cancer determined to be estrogen receptor (ER)-negative and progesterone receptor (PgR)-negative defined for this study as < 10% tumor staining by immunohistochemistry (IHC) (Note: Eligibility should be based on the ER and PgR status reported at the time of the most recent biopsy or resection).

• Breast cancer determined to be HER2-negative per current American Society of Clinical

Oncology/College of American Pathologists (ASCO/CAP) HER2 Guidelines (Note:

Eligibility should be based on the HER2 status reported at the time of the most recent biopsy or resection).

• At least one prior regimen for treatment of recurrent or metastatic disease (Note: Prior regimen for recurrent or metastatic disease is not required if the patient had disease progression or recurrence during or within the first 6 months following completion of adjuvant or neoadjuvant chemotherapy.)

• Measurable disease per RECIST v1.1

• Age ≥ 18 years

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Ability to swallow oral medications

• Adequate bone marrow function as defined below:

• Absolute neutrophil count (ANC) ≥ 1,200/mm3

• Platelet count ≥ 100,000/mm3

• Hemoglobin ≥ 9.0 g/dL, which must be stable in the opinion of the investigator without a history of transfusion dependence.

• Adequate renal function as defined below:

• Calculated creatinine clearance ≥ 45 mL/min

• Adequate hepatic function as defined below:

• Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for the laboratory

• Aspartate aminotransferase (AST) ≤ 3 x ULN for the laboratory, except in the presence of known hepatic metastasis, wherein the AST may be ≤ 5 x ULN

• Alanine aminotransferase (ALT) ≤ 3 x ULN for the laboratory, except in the presence of known hepatic metastasis, wherein the ALT may be ≤ 5 x ULN

• Serum B12 and folate levels ≥ lower limit of normal (LLN) for the laboratory (Note: Patients may begin B12 and folic acid supplementation and be reconsidered for participation in the study when levels are ≥ LLN for the laboratory).

• Ability to take folic acid, vitamin B12, and dexamethasone according to the protocol instructions

• Ability to interrupt chronic non-steroidal anti-inflammatory drugs (NSAIDs) beginning 2 days before (5 days before for long-acting NSAIDs) and continuing for 2 days following administration of each pemetrexed dose

• Toxicities from previous cancer therapies resolved to ≤ grade 1 unless specified otherwise in the inclusion or exclusion criteria

• Women who are not postmenopausal or have not undergone hysterectomy must have a documented negative serum pregnancy test within 7 days prior to initiating study treatment. Note: Postmenopausal is defined as one or more of the following:

• Age ≥ 60 years

• Age < 60 years and amenorrheic for at least 1 year with follicle-stimulating hormone (FSH) and plasma estradiol levels in the postmenopausal range

• Bilateral oophorectomy

• A woman of child-bearing potential (WCBP) and a male patient with partner who is a WCBP must agree to use a medically accepted method for preventing pregnancy for the duration of study treatment and for 2 months following completion of study treatment.

• Ability to understand and willingness to sign the consent form written in English

Exclusion Criteria

• Any investigational agent within 4 weeks prior to initiating study treatment

• Anticancer therapy within 2 weeks prior to initiating study treatment

• Plans for concurrent anticancer therapy except as permitted in Section 6.7.11

• Known or presumed intolerance of pemetrexed or sorafenib

• Known or suspected malabsorption condition or obstruction

• Brain metastases meeting either of the following exclusion criteria:

• Untreated brain metastases

• After completion of brain-directed therapy, the patient has not been able to tolerate discontinuation of steroids or a decrease in steroid dose

• Leptomeningeal metastasis

• Any documented history of clinically identifiable thrombotic, embolic, venous, or arterial events such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism within 6 months prior to initiating study treatment (Note: Patients with an asymptomatic catheter-related thrombus or a tumor-associated thrombus of locally-involved vessels or with incidental asymptomatic filling defects identified on imaging are not excluded.)

• Contraindication to antiangiogenic agents, including:

• Serious non-healing wound, non-healing ulcer, or bone fracture

• Major surgical procedure or significant traumatic injury within 4 weeks prior to initiating study treatment

• Pulmonary hemorrhage/bleeding event ≥ grade 2 (CTCAE v4.0) within 12 weeks prior to initiating study treatment

• Any other hemorrhage/bleeding event ≥ grade 3 (CTCAE v4.0) within 12 weeks prior to initiating study treatment

• Systolic blood pressure (BP) > 160 mmHg or diastolic BP > 100 mmHg despite optimal medical management

• QT interval, corrected (QTc) > 480 ms (≥ grade 2) on a 12-lead electrocardiogram (ECG)

• If baseline QTc on screening ECG is ≥ grade 2:

• Check potassium and magnesium serum levels

• Correct any identified hypokalemia and/or hypomagnesemia and repeat ECG to confirm exclusion of patient due to QTc

• For patients with heart rate < 60 bpm or > 100 bpm, manual read of the QT interval by a cardiologist is required, with Fridericia correction applied to determine QT interval with correction using Fridericia's formula (QTcF) which must be used to determine eligibility (Note: If heart rate is 60-100 bpm, manual read of the QT interval and correction to QTcF is not required).

• Active or clinically significant cardiac disease including any of the following:

• Unstable angina (eg, anginal symptoms at rest) or onset of angina within 3 months prior to initiating study treatment

• Myocardial infarction within 6 months prior to initiating study treatment

• Ventricular arrhythmias requiring anti-arrhythmic therapy other than beta blockers

• New York Heart Association (NYHA) class III or IV congestive heart failure

• Serious (ie, ≥ grade 3) uncontrolled infection

• Uncontrolled effusion

• Known human immunodeficiency virus (HIV) seropositivity (Note: HIV testing is not required)

• Chronic or active hepatitis B or C infection requiring treatment with antiviral therapy

• Seizure disorder requiring enzyme-inducing anti-epileptic drugs (EIAEDs) (Note: If the seizure disorder can be managed with agents that are not EIAEDs (eg, levetiracetam or valproate), the patient should not be excluded).

• Planned ongoing treatment with other drugs thought to potentially have adverse interactions with either of the study drugs; if such drugs have been used, patients must have discontinued these agents at least 2 weeks (or as noted below) prior to initiating study treatment. Examples include:

• STRONG CYP3A4 inducers

*Note: Examples of clinical inducers of cytochrome p450 (CYP) isozymes and classification of strong, moderate, and weak interactions are available through the

FDA website (Table 3-3 of website:):

http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteracti onsLabeling/ucm093664.htm

• Immunosuppressants (eg, tacrolimus, leflunomide, tofacitinib, roflumilast, pimecrolimus)

• NSAIDs (Note: NSAIDs must be discontinued within 5 days prior to initiating study treatment)

• Pregnancy or breastfeeding

• Previous malignancy with the following exceptions: adequately treated basal cell carcinoma or squamous cell carcinoma of the skin; any in situ malignancy; adequately treated Stage 1 and Stage 2 cancer from which the patient is currently in remission; any other cancer from which the patient has been disease-free for 3 years

• Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Virginia Commonwealth University/Massey Cancer Center	Richmond	Virginia	United States	23298

Sponsors and Collaborators

• Virginia Commonwealth University
• Eli Lilly and Company
• Bayer

Investigators

• Principal Investigator: Andrew S Poklepovic, MD, Massey Cancer Center

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Nov 22, 2017

More Information

Publications

None provided.

• Responsible Party: Virginia Commonwealth University
• ClinicalTrials.gov Identifier: NCT02624700
• Other Study ID Numbers: MCC-14-10790; HM20005967; NCI-2015-02190
• First Posted: Dec 8, 2015
• Last Update Posted: Jul 14, 2020
• Last Verified: Jun 1, 2020

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Keywords provided by Virginia Commonwealth University: ER-negative; PgR-negative; Human epidermal growth factor receptor 2 (HER2-negative); Triple Negative Breast Cancer; HER2-negative
• Additional relevant MeSH terms: Breast Neoplasms; Triple Negative Breast Neoplasms; Recurrence; Pemetrexed; Sorafenib

Study Results

Participant Flow

Arm/Group Title	A: Pemetrexed + Sorafenib	B: Pemetrexed + Sorafenib
Arm/Group Description	Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle Experimental Arm A: Pemetrexed: Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes. Experimental Arm A: Sorafenib: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.	Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21-days of each cycle. Experimental Arm B: Pemetrexed: Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes. Experimental Arm B: Sorafenib: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
Period Title: Overall Study
STARTED	9	4
COMPLETED	9	4
NOT COMPLETED	0	0

Baseline Characteristics

Arm/Group Title	A: Pemetrexed + Sorafenib	B: Pemetrexed + Sorafenib	Total
Arm/Group Description	Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle Experimental Arm A: Pemetrexed: Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes. Experimental Arm A: Sorafenib: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.	Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21 days of each cycle. Experimental Arm B: Pemetrexed: Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes. Experimental Arm B: Sorafenib: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.	Total of all reporting groups
Overall Participants	9	4	13
Age (Years) [Mean (Full Range) ]
Mean (Full Range) [Years]	54.89	56.75	55.46
Sex: Female, Male (Count of Participants)
Female	9 100%	4 100%	13 100%
Male	0 0%	0 0%	0 0%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	0 0%	0 0%
Not Hispanic or Latino	9 100%	4 100%	13 100%
Unknown or Not Reported	0 0%	0 0%	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%
Asian	0 0%	0 0%	0 0%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	3 33.3%	1 25%	4 30.8%
White	6 66.7%	3 75%	9 69.2%
More than one race	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	0 0%	0 0%
Region of Enrollment (participants) [Number]
United States	9 100%	4 100%	13 100%

Outcome Measures

1. Primary Outcome

Title	The Percentage of Patients With Objective Response Either Partial Response (PR) or Complete Response(CR).
Description	The primary endpoint is the percentage of patients with HER2-negative metastatic breast cancer achieving an objective response (either PR or CR). Overall Response = CR+PR, based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
Time Frame	2 years 3 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	A: Pemetrexed + Sorafenib	B: Pemetrexed + Sorafenib
Arm/Group Description	Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle Experimental Arm A: Pemetrexed: Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes. Experimental Arm A: Sorafenib: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.	Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21 days of each cycle. Experimental Arm B: Pemetrexed: Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes. Experimental Arm B: Sorafenib: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
Measure Participants	9	4
Partial Response	2 22.2%	1 25%
Stable Disease	1 11.1%	1 25%
Progressive Disease	5 55.6%	0 0%
Not Evaluable for Response	1 11.1%	2 50%

2. Secondary Outcome

Title	The Duration of Progression-free Survival (PFS).
Description	Progression-free survival (PFS) defined as the time (in days) from initiation of study treatment until documented disease progression or death, whichever occurs first.
Time Frame	2 years 3 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	A: Pemetrexed + Sorafenib	B: Pemetrexed + Sorafenib
Arm/Group Description	Pemetrexed 500mg/m2 IV Day 1 + Sorafenib 400mg PO BID Days 1-5, Every 14 Days	Pemetrexed 375mg/m2 IV Day 1 + Sorafenib 200mg PO BID Days 1-5, Every 21 Days
Measure Participants	9	4
Participant A	141	NA
Participant B	60	NA
Participant C	28	NA
Participant D	120	NA
Participant E	259	NA
Participant F	59	NA
Participant G	64	NA
Participant H	49	NA
Participant I	56	NA
Participant J	NA	22
Participant K	NA	100
Participant L	NA	160
Participant M	NA	19

3. Secondary Outcome

Title	The 2-year Survival Rate After Initial Study Treatment.
Description	The proportion of patients who are alive at 2 years following initiation of study treatment.
Time Frame	2 years 3 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	A: Pemetrexed + Sorafenib	B: Pemetrexed + Sorafenib
Arm/Group Description	Pemetrexed 500mg/m2 IV Day 1 + Sorafenib 400mg PO BID Days 1-5, Every 14 Days	Pemetrexed 375mg/m2 IV Day 1 + Sorafenib 200mg PO BID Days 1-5, Every 21 Days
Measure Participants	9	4
Count of Participants [Participants]	1 11.1%	0 0%

4. Secondary Outcome

Title	Number of Participants at Risk and Affected by Adverse Events (AEs)
Description	To further characterize the safety and side effect profile of the combination. All participants' AEs will be listed and summary descriptive statistics will be calculated.The Adverse events (AEs) are reported using criteria in the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).
Time Frame	2 years 3 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	A: Pemetrexed + Sorafenib	B: Pemetrexed + Sorafenib
Arm/Group Description	Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle Experimental Arm A: Pemetrexed: Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes. Experimental Arm A: Sorafenib: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.	Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21 days of each cycle. Experimental Arm B: Pemetrexed: Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes. Experimental Arm B: Sorafenib: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
Measure Participants	9	4
At Risk	9 100%	4 100%
Affected	9 100%	4 100%

Adverse Events

Time Frame	Adverse event data were collected over three years, four months.
Arm/Group Title	A: Pemetrexed + Sorafenib		B: Pemetrexed + Sorafenib
Arm/Group Description	Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle Experimental Arm A: Pemetrexed: Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes. Experimental Arm A: Sorafenib: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.		Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21 days of each cycle. Experimental Arm B: Pemetrexed: Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes. Experimental Arm B: Sorafenib: Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
All Cause Mortality
	A: Pemetrexed + Sorafenib		B: Pemetrexed + Sorafenib
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/9 (11.1%)		0/4 (0%)
Serious Adverse Events
	A: Pemetrexed + Sorafenib		B: Pemetrexed + Sorafenib
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	5/9 (55.6%)		3/4 (75%)
Blood and lymphatic system disorders
Anemia	1/9 (11.1%)	2	0/4 (0%)	0
Cardiac disorders
Sinus Tachycardia	1/9 (11.1%)	1	0/4 (0%)	0
Gastrointestinal disorders
Abdominal Pain	1/9 (11.1%)	1	2/4 (50%)	2
Constipation	1/9 (11.1%)	1	0/4 (0%)	0
Diarrhea	1/9 (11.1%)	1	0/4 (0%)	0
Gastrointestinal Disorders- Other, Specify	1/9 (11.1%)	1	0/4 (0%)	0
Nausea	1/9 (11.1%)	2	1/4 (25%)	1
Vomiting	1/9 (11.1%)	1	1/4 (25%)	1
General disorders
Fatigue	2/9 (22.2%)	2	0/4 (0%)	0
Fever	2/9 (22.2%)	2	0/4 (0%)	0
Malaise	1/9 (11.1%)	1	0/4 (0%)	0
Hepatobiliary disorders
Gallbladder Obstruction	0/9 (0%)	0	1/4 (25%)	1
Infections and infestations
Kidney Infection	1/9 (11.1%)	1	0/4 (0%)	0
Urinary Tract infection	1/9 (11.1%)	1	0/4 (0%)	0
Investigations
Alanine aminotransferase increased	0/9 (0%)	0	2/4 (50%)	2
Aspartate aminotransferase increased	0/9 (0%)	0	2/4 (50%)	2
Blood bilirubin increased	1/9 (11.1%)	1	2/4 (50%)	3
Investigations - Other, specify	0/9 (0%)	0	1/4 (25%)	1
Lymphocyte count decreased	1/9 (11.1%)	1	0/4 (0%)	0
Platelet count decreased	1/9 (11.1%)	2	0/4 (0%)	0
Metabolism and nutrition disorders
Acidosis	1/9 (11.1%)	1	0/4 (0%)	0
Dehydration	2/9 (22.2%)	3	0/4 (0%)	0
Hypoalbuminemia	1/9 (11.1%)	1	0/4 (0%)	0
Musculoskeletal and connective tissue disorders
Flank Pain	1/9 (11.1%)	1	0/4 (0%)	0
Generalized muscle weakness	1/9 (11.1%)	1	0/4 (0%)	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify	1/9 (11.1%)	1	0/4 (0%)	0
Nervous system disorders
Depressed level of consciousness	1/9 (11.1%)	1	0/4 (0%)	0
Psychiatric disorders
Confusion	1/9 (11.1%)	1	0/4 (0%)	0
Delirium	0/9 (0%)	0	1/4 (25%)	2
Respiratory, thoracic and mediastinal disorders
Dyspnea	2/9 (22.2%)	2	0/4 (0%)	0
Hypoxia	1/9 (11.1%)	1	0/4 (0%)	0
Respiratory failure	2/9 (22.2%)	2	0/4 (0%)	0
Vascular disorders
Hypotension	1/9 (11.1%)	1	0/4 (0%)	0
Thromboembolic event	1/9 (11.1%)	1	0/4 (0%)	0
Other (Not Including Serious) Adverse Events
	A: Pemetrexed + Sorafenib		B: Pemetrexed + Sorafenib
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	9/9 (100%)		4/4 (100%)
Blood and lymphatic system disorders
Anemia	9/9 (100%)	15	4/4 (100%)	5
Cardiac disorders
Atrial Fibrillation	1/9 (11.1%)	1	0/4 (0%)	0
Cardiac disorders - Other, specify	2/9 (22.2%)	3	0/4 (0%)	0
Sinus bradycardia	1/9 (11.1%)	1	0/4 (0%)	0
Sinus tachycardia	5/9 (55.6%)	11	3/4 (75%)	3
Supraventricular tachycardia	1/9 (11.1%)	1	0/4 (0%)	0
Eye disorders
Dry eye	1/9 (11.1%)	1	0/4 (0%)	0
Eye disorders - Other, specify	2/9 (22.2%)	2	0/4 (0%)	0
Retinal tear	1/9 (11.1%)	1	0/4 (0%)	0
Watering eyes	1/9 (11.1%)	1	0/4 (0%)	0
Gastrointestinal disorders
Abdominal pain	5/9 (55.6%)	7	2/4 (50%)	3
Ascites	0/9 (0%)	0	1/4 (25%)	1
Bloating	1/9 (11.1%)	1	1/4 (25%)	1
Cheilitis	0/9 (0%)	0	1/4 (25%)	3
Constipation	7/9 (77.8%)	10	3/4 (75%)	7
Diarrhea	2/9 (22.2%)	2	3/4 (75%)	7
Dry mouth	1/9 (11.1%)	1	2/4 (50%)	3
Dysphagia	1/9 (11.1%)	1	0/4 (0%)	0
Flatulence	3/9 (33.3%)	3	0/4 (0%)	0
Gastrointestinal disorders - Other, specify	1/9 (11.1%)	1	1/4 (25%)	2
Hemorrhoidal hemorrhage	1/9 (11.1%)	1	0/4 (0%)	0
Hemorrhoids	1/9 (11.1%)	1	0/4 (0%)	0
Ileal obstruction	0/9 (0%)	0	1/4 (25%)	1
Mucositis oral	2/9 (22.2%)	2	2/4 (50%)	6
Nausea	6/9 (66.7%)	10	4/4 (100%)	8
Vomiting	5/9 (55.6%)	7	3/4 (75%)	4
General disorders
Chills	2/9 (22.2%)	2	2/4 (50%)	3
Edema limbs	3/9 (33.3%)	3	1/4 (25%)	2
Edema trunk	1/9 (11.1%)	1	0/4 (0%)	0
Fatigue	7/9 (77.8%)	14	4/4 (100%)	10
Fever	3/9 (33.3%)	5	1/4 (25%)	1
General disorders and administration site conditions - Other, specify	1/9 (11.1%)	1	0/4 (0%)	0
Infusion related reaction	1/9 (11.1%)	1	0/4 (0%)	0
Malaise	5/9 (55.6%)	8	4/4 (100%)	6
Non-cardiac chest pain	2/9 (22.2%)	2	2/4 (50%)	2
Pain	2/9 (22.2%)	5	0/4 (0%)	0
Infections and infestations
Catheter related infection	1/9 (11.1%)	1	0/4 (0%)	0
Esophageal infection	1/9 (11.1%)	1	1/4 (25%)	1
Infections and infestations - Other, specify	1/9 (11.1%)	1	1/4 (25%)	1
Kidney infection	1/9 (11.1%)	1	0/4 (0%)	0
Lung infection	1/9 (11.1%)	2	1/4 (25%)	1
Mucosal infection	2/9 (22.2%)	2	2/4 (50%)	4
Skin infection	1/9 (11.1%)	1	1/4 (25%)	1
Upper respiratory infection	1/9 (11.1%)	1	0/4 (0%)	0
Urinary tract infection	2/9 (22.2%)	2	1/4 (25%)	2
Wound infection	1/9 (11.1%)	1	0/4 (0%)	0
Investigations
Activated partial thromboplastin time prolonged	1/9 (11.1%)	1	2/4 (50%)	3
Alanine aminotransferase increased	2/9 (22.2%)	3	2/4 (50%)	2
Alkaline phosphatase increased	4/9 (44.4%)	5	3/4 (75%)	6
Aspartate aminotransferase increased	3/9 (33.3%)	5	3/4 (75%)	4
Blood bilirubin increased	1/9 (11.1%)	3	1/4 (25%)	1
Creatinine increased	5/9 (55.6%)	8	1/4 (25%)	1
Electrocardiogram QT corrected interval prolonged	1/9 (11.1%)	1	0/4 (0%)	0
INR increased	1/9 (11.1%)	1	0/4 (0%)	0
Investigations - Other, specify	2/9 (22.2%)	6	1/4 (25%)	2
Lipase increased	0/9 (0%)	0	1/4 (25%)	1
Lymphocyte count decreased	5/9 (55.6%)	9	2/4 (50%)	4
Neutrophil count decreased	3/9 (33.3%)	3	0/4 (0%)	0
Platelet count decreased	4/9 (44.4%)	7	2/4 (50%)	2
Weight loss	2/9 (22.2%)	3	1/4 (25%)	2
White blood cell decreased	4/9 (44.4%)	6	2/4 (50%)	2
Metabolism and nutrition disorders
Alkalosis	1/9 (11.1%)	1	0/4 (0%)	0
Anorexia	8/9 (88.9%)	12	4/4 (100%)	5
Dehydration	5/9 (55.6%)	11	4/4 (100%)	8
Hyperkalemia	2/9 (22.2%)	4	0/4 (0%)	0
Hypermagnesemia	1/9 (11.1%)	1	0/4 (0%)	0
Hypoalbuminemia	6/9 (66.7%)	11	3/4 (75%)	4
Hypocalcemia	4/9 (44.4%)	6	2/4 (50%)	3
Hypoglycemia	2/9 (22.2%)	2	1/4 (25%)	1
Hypokalemia	4/9 (44.4%)	10	2/4 (50%)	2
Hypomagnesemia	6/9 (66.7%)	8	3/4 (75%)	3
Hyponatremia	4/9 (44.4%)	8	3/4 (75%)	3
Hypophosphatemia	3/9 (33.3%)	7	2/4 (50%)	4
Metabolism and nutrition disorders - Other, specify	0/9 (0%)	0	1/4 (25%)	1
Musculoskeletal and connective tissue disorders
Arthralgia	1/9 (11.1%)	1	1/4 (25%)	1
Back pain	5/9 (55.6%)	5	1/4 (25%)	1
Chest wall pain	2/9 (22.2%)	5	0/4 (0%)	0
Flank pain	0/9 (0%)	0	1/4 (25%)	1
Generalized muscle weakness	3/9 (33.3%)	4	0/4 (0%)	0
Muscle weakness lower limb	0/9 (0%)	0	1/4 (25%)	1
Musculoskeletal and connective tissue disorder - Other, specify	1/9 (11.1%)	1	0/4 (0%)	0
Myalgia	1/9 (11.1%)	2	0/4 (0%)	0
Neck pain	1/9 (11.1%)	2	0/4 (0%)	0
Pain in extremity	0/9 (0%)	0	1/4 (25%)	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor pain	0/9 (0%)	0	2/4 (50%)	4
Nervous system disorders
Cognitive disturbance	1/9 (11.1%)	1	0/4 (0%)	0
Dizziness	3/9 (33.3%)	6	1/4 (25%)	2
Dysgeusia	2/9 (22.2%)	4	2/4 (50%)	2
Encephalopathy	1/9 (11.1%)	1	0/4 (0%)	0
Headache	4/9 (44.4%)	6	3/4 (75%)	5
Intracranial hemorrhage	1/9 (11.1%)	1	0/4 (0%)	0
Lethargy	1/9 (11.1%)	1	0/4 (0%)	0
Paresthesia	0/9 (0%)	0	1/4 (25%)	2
Peripheral sensory neuropathy	1/9 (11.1%)	1	0/4 (0%)	0
Spasticity	0/9 (0%)	0	1/4 (25%)	1
Psychiatric disorders
Agitation	1/9 (11.1%)	1	0/4 (0%)	0
Anxiety	1/9 (11.1%)	1	2/4 (50%)	2
Confusion	1/9 (11.1%)	2	0/4 (0%)	0
Depression	1/9 (11.1%)	1	0/4 (0%)	0
Renal and urinary disorders
Dysuria	0/9 (0%)	0	1/4 (25%)	3
Acute kidney injury	2/9 (22.2%)	2	0/4 (0%)	0
Chronic kidney disease	1/9 (11.1%)	1	0/4 (0%)	0
Hematuria	2/9 (22.2%)	2	1/4 (25%)	1
Proteinuria	2/9 (22.2%)	3	2/4 (50%)	2
Renal and urinary disorders - Other, specify	0/9 (0%)	0	1/4 (25%)	1
Urinary frequency	1/9 (11.1%)	2	1/4 (25%)	2
Urinary incontinence	0/9 (0%)	0	1/4 (25%)	1
Urinary retention	1/9 (11.1%)	1	0/4 (0%)	0
Urinary tract pain	1/9 (11.1%)	1	0/4 (0%)	0
Urinary urgency	1/9 (11.1%)	1	2/4 (50%)	2
Reproductive system and breast disorders
Breast pain	3/9 (33.3%)	4	0/4 (0%)	0
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis	0/9 (0%)	0	1/4 (25%)	1
Atelectasis	2/9 (22.2%)	2	0/4 (0%)	0
Bronchial stricture	0/9 (0%)	0	1/4 (25%)	1
Cough	3/9 (33.3%)	3	3/4 (75%)	3
Dyspnea	6/9 (66.7%)	10	3/4 (75%)	3
Epistaxis	0/9 (0%)	0	1/4 (25%)	1
Hiccups	1/9 (11.1%)	1	0/4 (0%)	0
Hoarseness	2/9 (22.2%)	2	1/4 (25%)	1
Hypoxia	1/9 (11.1%)	1	1/4 (25%)	1
Nasal congestion	1/9 (11.1%)	2	0/4 (0%)	0
Pleural effusion	3/9 (33.3%)	4	0/4 (0%)	0
Postnasal drip	2/9 (22.2%)	3	0/4 (0%)	0
Productive cough	3/9 (33.3%)	4	0/4 (0%)	0
Respiratory, thoracic and mediastinal disorders - Other, specify	2/9 (22.2%)	3	1/4 (25%)	1
Sore throat	0/9 (0%)	0	2/4 (50%)	3
Wheezing	2/9 (22.2%)	2	1/4 (25%)	1
Skin and subcutaneous tissue disorders
Dry skin	1/9 (11.1%)	2	0/4 (0%)	0
Palmar-plantar erythrodysesthesia syndrome	4/9 (44.4%)	5	0/4 (0%)	0
Pruritus	3/9 (33.3%)	3	0/4 (0%)	0
Rash acneiform	3/9 (33.3%)	4	0/4 (0%)	0
Rash maculo-papular	2/9 (22.2%)	2	1/4 (25%)	1
Scalp pain	1/9 (11.1%)	1	0/4 (0%)	0
Skin and subcutaneous tissue disorders - Other, specify	4/9 (44.4%)	4	0/4 (0%)	0
Skin hyperpigmentation	1/9 (11.1%)	1	0/4 (0%)	0
Skin ulceration	1/9 (11.1%)	1	0/4 (0%)	0
Vascular disorders
Flushing	1/9 (11.1%)	1	0/4 (0%)	0
Hot flashes	1/9 (11.1%)	1	0/4 (0%)	0
Hypertension	4/9 (44.4%)	9	1/4 (25%)	4
Hypotension	3/9 (33.3%)	7	0/4 (0%)	0
Thromboembolic event	0/9 (0%)	0	1/4 (25%)	1

Limitations/Caveats

Incomplete objectives due to early termination of trial. Amendment to allow more heavily pretreated subjects to be enrolled required a change in starting doses (Arm B) for all subsequently enrolled subjects.

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.